---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-058666"
form_type: "8-K"
ticker: "CHRS"
cik: "0001512762"
company_name: "Coherus Oncology, Inc."
filed_at: "2026-05-11T20:16:20+00:00"
generated_at: "2026-05-11T22:08:11.083381+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Coherus Q1 LOQTORZI rev $11.8M (+61% YoY); net loss $36.9M; pipeline readouts mid-2026

## Summary
- LOQTORZI net revenue $11.8M in Q1 2026, up 61% YoY from $7.3M but down 5% from Q4 2025 $12.4M due to weather and seasonality.
- GAAP net loss from continuing ops $36.9M ($(0.27) diluted EPS) vs $47.4M ($(0.41)) in Q1 2025; non-GAAP net loss $33.9M ($(0.25)).
- Cash, cash equivalents and marketable securities $167.0M; Q1 equity offering of 32.89M shares raised net proceeds of $53.6M.
- Casdozokitug Phase 2 1L HCC fully enrolled, first data readout expected mid-2026; tagmokitug combo studies with initial data mid-2026 and 2H 2026.
- Q1 recorded highest new patient starts for LOQTORZI; average treatment duration growing; LOQTORZI remains only FDA-approved treatment for NPC.

## SEC filing metadata
- accession: 0001104659-26-058666
- form_type: 8-K
- ticker: CHRS
- cik: 0001512762
- company_name: Coherus Oncology, Inc.
- filed_at: 2026-05-11T20:16:20+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1512762/000110465926058666/0001104659-26-058666-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1512762/000110465926058666/chrs-20260511x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-058666
- JSON: https://secwatch.observer/filing/0001104659-26-058666.json
- Plain text: https://secwatch.observer/filing/0001104659-26-058666.txt

## Key facts
- Earnings Releases
  Coherus Oncology, Inc. reported financial results for first quarter 2026.
  - Period: first quarter 2026
  - Result: reported results
  source text: On May 11, 2026, Coherus Oncology, Inc. (the “Company”) issued a press release regarding its financial results for the quarter ended March 31, 2026.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1512762/000110465926058666/0001104659-26-058666-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.